Aether Pacific Pharmaceuticals expands into Australian market by launching NZ-grown medicinal cannabis products. The move follows completion of regulatory requirements, making three strains available to Australian patients via prescription. Cannabis is cultivated to meet Australian regulations and EU-cGMP standards, with THC content ranging from 17% to 25%. Aether collaborates with Melbourne-based Novachem for distribution and plans further educational initiatives.
Read the full story here
Written by: Stu Finlayson
Published on March 13, 2024 at 08:46AM
Source: Cannabiz (opens in new tab)